Attached files

file filename
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex31-2.htm
10-Q - QUARTERLY REPORT - Adamis Pharmaceuticals Corpadmp-10q_063020.htm
EX-32.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex32-2.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex31-1.htm
EX-10.6 - DISTRIBUTION AND COMMERCIALIZATION AGREEMENT - Adamis Pharmaceuticals Corpex10-6.htm
EX-10.3 - LICENSE AGREEMENT - Adamis Pharmaceuticals Corpex10-3.htm
EX-10.2 - TRANSITION SERVICE AGREEMENT - Adamis Pharmaceuticals Corpex10-2.htm
EX-10.1 - TERMINATION AND TRANSFER AGREEMENT - Adamis Pharmaceuticals Corpex10-1.htm
 

Adamis Pharmaceuticals Corporation 10-Q

 

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

The undersigned, Dennis J. Carlo, the Chief Executive Officer of Adamis Pharmaceuticals Corporation (the “Company”), pursuant to 18 U.S.C.  1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

(1) the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ DENNIS J. CARLO
  Dennis J. Carlo
  Chief Executive Officer

Dated: August 17, 2020

This certification is being furnished to the SEC with this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.